Clinical outcomes in 2 patients treated with eculizumab and emapalumab for graft rejection. Two patients in our cohort (19 and 22) experienced high fevers again after their second HCT. Based on our data showing elevated interferon and terminal compliment activation in graft rejection with high fevers, each of these patients received 1-time doses of eculizumab and emapalumab at the time of fever and both maintained engraftment. ANC, absolute neutrophil count; MP, methylprednisolone.